Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018053517) INHIBITORS OF LDLR-PCSK9 PROTEIN-PROTEIN INTERACTION AND METHODS OF THEIR USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/053517 International Application No.: PCT/US2017/052292
Publication Date: 22.03.2018 International Filing Date: 19.09.2017
IPC:
C07D 241/04 (2006.01) ,C07D 241/12 (2006.01) ,C07D 403/06 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
241
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02
not condensed with other rings
04
having no double bonds between ring members or between ring members and non-ring members
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
241
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
02
not condensed with other rings
10
having three double bonds between ring members or between ring members and non-ring members
12
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
Applicants:
THE TEXAS A&M UNIVERSITY SYSTEM [US/US]; 3369 Tamu College Station, TX 77843-3369, US
Inventors:
BURGESS, Kevin; US
Agent:
RENZONI, George, E.; US
Priority Data:
62/396,65819.09.2016US
Title (EN) INHIBITORS OF LDLR-PCSK9 PROTEIN-PROTEIN INTERACTION AND METHODS OF THEIR USE
(FR) INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE LDLR-PCSK9 ET LEURS PROCÉDÉS D'UTILISATION
Abstract:
(EN) Compounds that disrupt the interaction between PCSK9 and LDLR, compositions that include the compounds, and methods for making and using the compounds and compositions.
(FR) L'invention concerne des composés qui perturbent l'interaction entre PCSK9 et LDLR, des compositions qui comprennent les composés, et des procédés de fabrication et d'utilisation des composés et des compositions.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)